A case series published in Annals of Internal Medicine finds that a fourth dose of an mRNA-based vaccine produces a satisfactory antibody response in some kidney transplant recipients who did not respond adequately after 3 previous doses. These findings support the use of a fourth vaccine dose for such patients.
Researchers from University Hospital of Strasbourg studied 92 kidney transplant recipients at 3 independent French university hospitals to investigate whether a fourth dose of an mRNA-based anti–SARS-CoV-2 vaccine would increase antispike IgG titers in kidney transplant recipients who showed a weak serologic response after 3 doses.
The patients, who had antispike IgG titers less than 143 BAU/mL 1 month after a third dose of vaccine were given a fourth dose of mRNA vaccine and then measurement of antispike IgG titers were taken 2 to 6 weeks later. The researchers found no safety concerns with the fourth dose and noted that after a median of 29 days, median antispike IgG levels increased significantly, suggesting that a fourth dose of vaccine may be warranted in these patients.
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series, Annals of Internal Medicine (2022). DOI: 10.7326/L21-0598
American College of Physicians
A fourth dose of mRNA-based vaccine may be warranted in some kidney transplant recipients (2022, January 10)
retrieved 10 January 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.